ARCH — Arch Biopartners Share News
0.000.00%
Last trade - 00:00- CA$57.06m
- CA$59.79m
- CA$0.28m
Brief: Arch Biopartners Files New Patent Application For Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
Brief: Arch Biopartners Enters Into Worldwide License Agreement With Telara Pharma To Re-Purpose Cilastatin For Treatment & Prevention Of Acute Kidney Injury
Brief: Arch Biopartners Enters Exclusive License Agreement With The University Of Cincinnati
Brief: Arch Biopartners Receives Health Canada Authorization To Amend Phase Ii Trial Protocol For Lsalt Peptide
Brief: Arch Biopartners Receives Ethics Committee Approval In Turkey To Dose Additional Patients In The Phase II Trial For LSALT Peptide
Brief: University Of Calgary Joins The Phase Ii Trial Of Lsalt Peptide For The Treatment Of Complications In Hospitalized Covid-19 Patients
Brief: Arch Biopartners Receives Government Of Canada Funding To Support Phase II Therapeutic Trial Of Metablok For Covid-19
Brief: Arch Biopartners Inc Says Veterans Affairs San Diego Healthcare System Has Started Recruiting Patients For Phase II Trial Of Its Lead Drug LSALT Peptide
Brief: Arch Biopartners Announces Dosing Of First Patient In Turkey In Phase II Trial Of LSALT Peptide To Treat COVID-19 Complications
Brief: First Patient Dosed In Phase Ii Trial To Treat Complications In Covid-19
Brief: Arch Biopartners Receives Approval From Turkish Ministry Of Health To Proceed With Phase II Trial For Lsalt Peptide
Brief: Arch Biopartners Obtains DTC Eligibility For Its Common Shares On OTCQB
Brief: Arch Biopartners Receives Independent Institutional Review Board Approval For Phase Ii Trial For Lsalt Peptide
Brief: Broward Health Medical Center Becomes First Clinical Site In U.S. For Phase Ii Trial For Lsalt Peptide
Brief: Arch Biopartners Engages Global CRO to Conduct LSALT Peptide Phase II Trial For Treatment Of Complications In Covid-19 Patients In U.S.
Brief: Arch Biopartners Announces FDA Acknowledgement Of Investigational New Drug Application For Metablok
Brief: Arch Biopartners Submits IND Application For Metablok
Brief: Arch Biopartners Expands Main Goal Of Phase II Trial For Lead Drug LSALT Peptide In Patients With COVID-19
Brief: Arch Biopartners Discloses New Patent Filing For Novel Drug Candidates To Prevent Lung Inflammation